Loading...
Although androgen-deprivation therapy (ADT) remains the standard of care in metastatic prostate cancer, essentially all patients ultimately develop castration resistance and disease progression. Docetaxel (with prednisone) was FDA approved in 2004 for patients with castration-resistant disease after phase III trials demonstrated improvements in both overall survival and disease-related symptoms (e.g., N Engl J Med 2004; 351:1502). However, the optimal timing of docetaxel administration is undefined.
To determine if early use of docetaxel is beneficial in this setting prior to development of castration-resistant disease, European investigators conducted a multicenter, phase III trial involving patients with histologically confirmed adenocarci…